Wednesday, March 20, 2024 CCTG BRC.7 INSIGNA: A Randomized, Phase III Study of First line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis was officially closed to further accrual after meeting its accrual goal with CCTG centres contributing 50 patients to the study, 8% of the final accrual of 607. This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. For more information please visit the CCTG BRC7 members trial page.
